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Abstract
The Wilms’ tumor suppressor gene (WT1) has been identified as an oncogene in many malignant diseases such as
leukaemia, breast cancer, mesothelioma and lung cancer. However, the role of WT1 in non-small-cell lung cancer (NSCLC)
carcinogenesis remains unclear. In this study, we compared WT1 mRNA levels in NSCLC tissues with paired corresponding
adjacent tissues and identified significantly higher expression in NSCLC specimens. Cell proliferation of three NSCLC cell
lines positively correlated with WT1 expression; moreover, these associations were identified in both cell lines and a
xenograft mouse model. Furthermore, we demonstrated that up-regulation of Cyclin D1 and the phosphorylated
retinoblastoma protein (p-pRb) was mechanistically related to WT1 accelerating cells to S-phase. In conclusion, our findings
demonstrated that WT1 is an oncogene and promotes NSCLC cell proliferation by up-regulating Cyclin D1 and p-pRb
expression.
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Introduction
Lung cancer continues to be a major public health problem in
both men and women, it is currently the cancer type with the
highest mortality worldwide. The incidence has increased rapidly
due to extensive tobacco smoking [1–3], and in China there has
been a 26.9% increase in men and 38.4% in women over the past
five years [4]. Non-small cell lung cancer (NSCLC) includes
several histological subgroups, adenocarcinoma, squamous cell
and large cell carcinoma, that comprise 80–85% of the total
incidence, whereas the remaining cases include the more distinct
group of small-cell lung cancer (SCLC) [2,5–7]. In this study, we
focus on the role of WT1 in the development and carcinogenesis of
NSCLC.
The Wilms’ tumor gene (WT1) which is located at 11p13q,
encodes a 52–54 kDa protein that containing four zinc finger
transcriptional factors and was first identified as a tumor
suppressor gene in nephroblastoma or Wilms’ tumor, a pediatric
kidney cancer [8,9]. Overexpression of this gene was also
discovered in several leukemias and solid tumours, as breast
cancer, lung cancer and mesothelioma, and it was hypothesized
that this gene plays an oncogenic role [10,11]. Oji Y et al
suggested that WT1 plays an important role in the growth of
normal lung cells; overexpression of WT1 disturb the growth and
differentiation of normal lung cells and, according to their
findings, lead to lung cancer [11]. WT1 has been demonstrated
to play a role in the regulation of cell proliferation and apoptosis in
many biological and pathological mechanisms. Recently, it has
been investigated as a potential target of immunotherapy for
several cancer types, including NSCLC and mesothelioma [12].
Signal transducers and activators of transcription 3 (STAT3)
have been reported to be overexpressed in many human
malignancies and activated by various cytokines and growth
factors during cancer development and progression [13,14]. It has
been demonstrated that STAT3 promotes cancer cell proliferation
via up-regulation of genes encoding apoptosis inhibitors, such as
Mcl-1 and Bcl-xL and cell-cycle regulators including the cyclins
D1/D2 and c-Myc [13–17]. Interestingly Rong et al demonstrat-
ed evidence that WT1enhanced the transcriptional activity of
phosphorylated STAT3 (p-STAT3) leading to synergistic up-
regulation of downstream genes including cyclin D1 and Bcl-xL, in
mouse fibroblasts, melanoma and hepatic cells as well as human
embryonic kidney cells [18]. However, WT1 has not been
previously reported in lung cancer cell lines.
In this study, we aimed to identify the expression of WT1
protein in NSCLC specimens compared to adjacent tissues,
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e68837
investigate the proliferation promoting function of WT1 in vitro
and in vivo and identify its relationship with p-STAT3 transcrip-
tional activation.
Materials and Methods
Patients
NSCLC and corresponding adjacent tissues included in this
study were obtained from 85 consecutive patients who had de
novo disease and undergone surgical resection. They were
included between December 2010 and April 2011 at the First
Affiliated Hospital of Nanjing Medical University (Nanjing,
China). The correct diagnosis was assessed by an experienced
pathologist and the staging of NSCLC by a clinical oncologist
according to the International Association for the Study of Lung
Cancer (IASLC) 7th TNM-classification. Adjacent tissue was
located within 3 cm of the edge of the tumor tissue.
RT-PCR
RNA was obtained from snap-frozen tissues and NSCLC cell
lines using Trizol (Invitrogen, Carlsbad, CA, USA) method
following the manufacture’s protocol. RNA concentrations and
qualities were examined by Beckman Coulter DU800 spectro-
photometer (Beckman, Brea, CA, USA). cDNA were synthesized
with a PrimescriptTM RT reagent kit (TaKaRa, Japan). 12 mL of
total RNA mixed with 8 mL Primescript buffer and 20 mL DEPC-
treated water was incubated at 37uC for 15 min, 85uC for 5 s and
stored at 4uC until use.
Figure 1. Up-regulation of WT1 in non-small cell lung cancer tissues. A, Immunohistochemical staining of WT1 in tumor (left) and adjacent
(right) specimens. B, Average value of integrated optical density (IOD) was assessed by analyzing five fields per slide and recorded in the histogram.
C, Real-time PCR analysis of WT1 mRNA level in tumor and adjacent tissues relative to b-actin. Data are represented as mean6SD. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0068837.g001
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qRT-PCR
ABI Prism7500 Sequence Detector System (ABI, USA) was
employed to determine the relative level of mRNA in tumor tissues
and adjacent tissues. Quantitative real-time polymerase chain
reaction (qRT-PCR) analysis for WT1 and b-actin was performed
with SYBRH Premix ExTaqTM (TaKaRa, Japan) according to the
manufacturer’s instructions. PCR was performed using 10 ml
26Premix buffer, 0.5 ml of each 59 and 39 primer, and 1 ml
samples or distilled water to a final volume of 20 ml. Each vial was
denatured at 95uC for 1 min. denatured at 95uC for 15 sec,
annealed at 60uC for 15 sec and extended at 72uC for 30 sec using
the following primers: WT1 forward primer, 59GCTATTCG-
CAATCAGGGTTACAG39; WT1 reverse primer,
59TGGGATCCTCATGCTTGAATG39. b-actin forward pri-
mer,59CCCAGCACAATGAAGATCAAGATCAT39; b-actin re-
verse primer: 59ATCTGCTGGAAGGTGGACAGCGA39; at the
end of the extension phase, fluorescence detection was performed.
To discriminate specific from nonspecific cDNA products, a
melting curve was obtained at the end of each run.
Cell Culture
A549, H1299, H1650 and 293T cell lines (ATCC) were
employed for the present study. A549, H1299 and H1650 were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA, USA), while 293T were
cultured in DMEM high glucose medium supplemented with 10%
fetal bovine serum. All cells were maintained in a humidified 37uC
incubator with 5% CO2.
Lentivirus Production and Transduction
WT1A (-17aa-KTS isoform) gene was synthesized (purchased
from Genscript, Piscataway, NJ) with restrictive digestion using
Mlu I and subcloned pLV-GFP plasmid (gift from D. Beicheng
Sun, University of Nanjing Medical University, China), and
named pLV-GFP-WT1. To generate plasmid expressing WT1-
shRNA, double-stranded oligonucleotides were cloned into
pLL3.7 vector (gift from D. Yun Chen, University of Nanjing
Medical University, China) and named pLL3.7-WT1-shRNA.
The sequences of WT1-shRNA used are aac TCAGGGTTA-
CAGCACGGTC ttcaagaga GACCGTGCTGTAACCCTGA
tttttt c. The uppercase letters represent WT1 specific sequence
and lowercase letters represent hairpin sequences. Recombinant
lentivirus was generated from 293T cells using calcium phosphate
precipitation. A549, H1299, H1650 were transfected with
lentivirus using polybrene (8 ug/ml). Representative pictures of
wild-type and transfected cells are shown in Figure S1.
Western-blotting Assay
Proteins were extracted from cultured cells and mice tissues,
quantitated using a protein assay (BCA method, Beyotime, China).
Proteins were fractionated by SDS-PAGE, transferred to PVDF
membrane, blocked in 4% dry milk at room temperature for 1
hour and immunostained with primary antibodies at 4uC
overnight using anti-WT1 (1:1000, 6F-H2, Millipore, USA),
anti-STAT3/p-STAT3 (1:2000, Cell Signalling Technology,
Beverly, MA, USA), anti-Cyclin D1 (1:500, Santa Cruz Biotech-
nology, Delaware Avenue, CA, USA), anti-p-pRb (1:1000, Cell
Signaling Technology, Beverly, MA, USA), anti-caspase3 (1:3000,
Abcam, Cambridge, MA, USA), anti-Bcl-2L (1:1000, Abcam,
Cambridge, MA, USA) and anti-GAPDH (1:1000, Kangchen,
Figure 2. WT1 promotes NSCLC cell proliferation in vitro. AWT1 expression of NSCLC wild-type cells and NSCLC cells transfected by lentivirus
containing pLL3.7 (GFP1), pLV-GFP (GFP2), pLL3.7-WT1-shRNA (WT1-shRNA1, WT1-shRNA2, WT1-shRNA3) and pLV-GFP-WT1 (WT1) by western-blot. B,
The viability of NSCLC cells was assessed by CCK-8 assay: overexpression of WT1 promotes the cell viability while inhibition of WT1 expression
reduces the effect. Data are represented as mean6SD. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0068837.g002
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Figure 3. WT1 accelerates the S-phase entry of cell cycle by up-regulating Cyclin D1 and p-pRb. A, Cell cycle analysis of NSCLC wild-type
cells and transduced with WT1-shRNA or WT1. Wild-type cells were used as control. B, The S-phase/G1-phase analysis was calculated and recorded in
the histograms. C, Cell apoptosis analysis of NSCLC wild-type cells and those transduced with WT1-shRNA or WT1. Wild-type cells were used as
control. D, Western-blotting analysis of expression of WT1, STAT3, p-STAT3 (S727 and Y705), Cyclin D1, p-pRb, caspase3, Bcl-2L in indicated NSCLC
cells. GAPDH was used as a loading control. Data are represented as mean6SD. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0068837.g003
WT1 Promotes NSCLC Cell Proliferation
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China). The results were visualized via a chemiluminescent
detection system (Pierce ECL Substrate Western blot detection
system, Thermo, Pittsburgh, PA, USA) and exposed in Molecular
Imager ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA).
Cell Counting Kit-8 (CCK-8) Assay
Cells were seeded into 96-well plates (6.06103 cells/well). Cell
viability was assessed by CCK-8 assay (Beyotime institute of
biotechnology, China). The absorbance of each well was read on a
spectrophotometer (Thermo, Pittsburgh, PA, USA) at 450 nm
(A450). Three independent experiments were performed in
quintuplicate.
Flow Cytometric Analysis
Flow cytometric analysis was taken to detect the apoptosis and
cell cycle status. The cells were harvested, washed twice, and
resuspended in 100 mL of PBS containing 3 mL of annexin V and
3 mL of PI (KeyGen, China) according to the manufacturer’s
recommendation. The apoptosis data acquisition and analysis
were performed by the flow cytometry facility (BD Biosciences,
San Jose, CA).
Cell cycle analysis was assessed by DNA content detected using
the flow cytometry facility (BD Biosciences, San Jose, CA, USA).
After collected by trypsinization, the cells were suspended with
70% ethanol and kept at 4uC for 30 min. Filtered through the
mesh, and the DNA content of the stained nuclei was analysed. All
experiments were performed three times to assure the results
facticity.
Tumorigenicity in Nude Mice
To investigate the effects of WT1 on tumor growth in vivo, we
established the xenograft model in 4-week-old Balb/cnu/nu mice.
We employed 90 Balb/cnu/nu mice (purchased from model animal
research center of Nanjing University in China) in this study and
divided them into 5 groups randomly (n = 6 per group) for each
cell line (A549/H1299/H1650). All cells were tripsinized and
resuspended with 100 mL of PBS (containing 50 mL Matrigel)
respectively and subcutaneously injected into the axilla of each
Figure 4. WT1 promotes the growth of tumor xenografts in vivo. A, Tumor volume of Balb/cnu/nu nude mice 31 days after NSCLC cells
injection. B, Tumor tissues obtained from nude mice presented in bright light (left) and in vivo fluorescence image system. C, WT1 expression in
tumor tissues from nude mice by Western-blotting analysis. Data are represented as mean6SD. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0068837.g004
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Figure 5. WT1 up-regulates the expression of Cyclin D1 and p-pRb in vivo. A, Immunohistochemical staining of WT1, p-STAT3 (s727), Cyclin
D1 and p-pRb in WT1 overexpressed (WT1) tumor tissues and WT1 down-regulated (WT1-shRNA) tumor tissues in vivo. Average value of integrated
optical density (IOD) was obtained as described above, demonstrated that the expression of Cyclin D1 and p-pRb was significantly up-regulated. B,
WT1 Promotes NSCLC Cell Proliferation
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nude mouse (56106 cells per mouse). One week after injection,
tumors dimensions were measured every 4 days and after one
month all mice were sacrificed and tumors were obtained (Figure
S2). The volume was calculated using following formula:
volume= length6width260.5.
Immunohistochemistry
Tissues were fixed in 4% paraformaldehyde and cut from
paraffin block to 5 mm thickness. After dewaxing with xylene and
rehydration with a graded series of ethanol, the slides were heated
in the autoclave for three minutes using citrate buffer (PH 6.0) and
incubated with primary antibody WT1(1:100, 6F-H2, Millipore,
USA), p-STAT3 (1:400, Cell Signalling Technology, Beverly, MA,
USA), Cyclin D1 (1:50, Santa Cruz Biotechnology, Delaware
Avenue, CA, USA) and p-pRb (1:100,Cell Signaling Technology,
Beverly, MA, USA) at 4uC overnight. Blocking serum or antibody
dilution buffer were prepared as Negative controls. The primary
antibodies utilized were all the same as for Western blot analysis.
Photographs were taken by microcope (Nikon, ECLIPSE 50i) and
software NIS-Elements v4.0. Average values of integrated optical
density (IOD) were obtained from five random fields per slide by
using Image-Pro Plus software (v5.0). Every data was detected
three times at least.
Statistical Analysis
Data was presented as mean6SD based on three separated
experiments. The Student’s t-test, ANOVA and two-sided Fisher
exact test was used to evaluate the statistical significance of
differences in all pertinent experiments. A value of P,0.05 was
considered as statistical significance, and P,0.001 was considered
highly significant. All statistical analyses were analyzed using the
SPSS program v17.0 (SPSS, Chicago, IL, USA).
Western-blotting analysis of expression of WT1, STAT3, p-STAT3 (S727 and Y705), Cyclin D1, p-pRb in indicated tumors. GAPDH was used as a loading
control. Data are represented as mean6SD. *P,0.05.
doi:10.1371/journal.pone.0068837.g005
Figure 6. WT1 enhances the expression of Cyclin D1 and p-pRb in NSCLC specimens. Immunohistochemical staining of WT1, p-STAT3
(s727), Cyclin D1 and p-pRb in WT1 overexpression (Case 1) tumor tissues and WT1 low expression (Case 2) tumor tissues in vivo. Average value of
integrated optical density (IOD) was obtained as described above, demonstrated that the expression of Cyclin D1 and p-pRb was significantly up-
regulated. Data are represented as mean6SD. *P,0.05.
doi:10.1371/journal.pone.0068837.g006
WT1 Promotes NSCLC Cell Proliferation
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Results
1. WT1 mRNA Levels were Overexpressed in NSCLC
Specimens
We investigated 85 pairs of NSCLC and corresponding
adjacent specimens using immunohistochemistry and real-time
PCR. The clinical characteristics of the patients are shown in
Table S1. WT1 expression in tumors was significantly higher
compared to adjacent tissues. Representative pictures are shown in
Figure 1A. Statistical analysis of IOD values of 85 slides stained
with WT1 is shown in the histogram in Figure 1B (*p,0.05). As
illustrated in Figure 1C, the mRNA level of WT1 was significantly
overexpressed in NSCLC specimens (**p,0.001). Additionally,
our findings indicated that WT1 mRNA level was associated both
with tumor versus normal and with tumor stage, see Table
S1(**p,0.001). Taken together, these results are in concordance
with previous findings indicating that higher expression of WT1 is
associated with NSCLC.
2. WT1 Expression Promoted the Viability of NSCLC Cell
Lines in vitro
To find a WT1-shRNA that could effectively down-regulate the
expression of WT1 in NSCLC cell lines, three candidate WT1-
shRNA (Table S2) were synthesized and tested using Western-blot
analysis and real-time PCR. We found that WT1-shRNA3re-
pressed the expression of WT1 in A549/H1299/H1650 with
maximum efficiency (Figure 2A). Then, we detected the expression
of WT1 in all cell lines to confirm the lentivirus by Western-blot
analysis and real-time PCR. We found that the expression of WT1
in A549/H1299/H1650 transduced with pLL3.7-WT1-shRNA
was much lower compared of the controls; simultaneously, the
expression of WT1 in A549/H1299/H1650 transduced with
pLV-GFP-WT1 was much higher compared to the controls. We
also found that the two vectors (pLL3.7-WT1 and pLV-GFP) had
no effect on the expression of WT1 (Figure 2A and Figure S3).
Next, we conducted CCK-8 assay to test viability; the results
indicated that overexpression of WT1 enhanced cell viability,
whereas down-regulation of WT1 exhibited the opposite effect and
the discrepancy was increasingly evident over time (Figure 2B).
Therefore, these findings indicated that WT1 promoted NSCLC
cell viability in vitro.
3. WT1 Expression Accelerated S-phase Entry of Cell Cycle
by Up-regulating Cyclin D1 and p-pRb Protein
To investigate the mechanism by which WT1 promoted
NSCLC cell proliferation, we studied the effects of WT1
expression on the cell cycle via flow cytometric analysis. The
results showed that the percentage of S-phase in WT1 overex-
pression group was higher compared to the control, whereas the
WT1 knockdown group was lower (Figure 3A&3B). This result
suggested that WT1 potentially promoted NSCLC cell prolifer-
ation by accelerating S-phase entry of cell cycle.
In order to further elucidate the mechanism, we detected the
expression of Cyclin D1 and p-pRb because this activity is
required for cell cycle G1/S transition by Western-blot. As
illustrated in Figure 3D, Cyclin D1 and p-pRb protein were both
increased in WT1 overexpressing cells and reduced in WT1 down-
regulated cells. Based on WT1, enhanced transcriptional activity
of p-STAT3, and other findings by Rong et al, we detected the
activity of STAT3 and p-STAT3 (S727 and Y705) and found that
phosphorylation of both S727 and Y705 was overexpressed in all
cell lines. However, to date, there are no reports that have
investigated whether WT1 is associated with the phosphorylation
of STAT3. Additionally, we also detected apoptosis and did not
find any effect of WT1 (Figure 3C&3D). Taken together, our
findings suggest that WT1 accelerates S-phase entry of cell cycle
by up-regulating Cyclin D1 and p-pRb protein expression.
4. WT1 Expression Promoted the Growth of Tumor
Xenografts in vivo
To determine whether WT1 affected NSCLC progression
in vivo, we established a xenograft tumor model using Balb/cnu/nu
mice. Mice were subcutaneously injected with stably pLV-GFP-
WT1 and pLL3.7-WT1-shRNA infected A549/H1299/H1650
cells at a single site, respectively with empty plasmid and wild-type
WT1 as controls. As illustrated in Figure 4A, we found that there
were no significant differences between wild-type cells and cells
transduced with pLV-GFP and pLL3.7-GFP; this indicated that
the tumor growth curve in the cells transduced with pLV-GFP-
WT1 was markedly increased compared with control, while the
tumor growth curve in cells transduced with pLL3.7-WT1-shRNA
was significantly inhibited. Tumor tissues obtained from nude
mice were presented in bright light (Figure 4B left) and in vivo
fluorescence image system (Figure 4B right). Significant increases
in tumor volume were found when cells were transduced with
pLV-GFP-WT1 compared to wild-type cells; in contrast, tumor
volume of cells transduced with pLL3.7-WT1-shRNA was
significantly decreased. Additionally, we detected the expression
of WT1 protein in tumors obtained from nude mice by Western-
blot analysis. We found that it there was no change compared to
cells in vitro (Figure 2A right and Figure 4C). These results suggest
that WT1 promotes growth of subcutaneous implant tumor
in vivo.
5. WT1 Affected the Expression of Cyclin D1 and p-pRb
in vivo
In vivo, we further validated our in vitro results in which WT1
accelerated S-phase entry of cell cycle by up-regulating Cyclin D1
and p-pRb. We investigated the expression of STAT3, p-STAT3
(S727), Cyclin D1 and p-pRb in tumors obtained from nude mice
via immunohistochemical staining and Western-blot analysis. As
shown in Figures 5A and 5B, the Cyclin D1 and p-pRb levels were
increased in WT1 overexpressing tissues compared to WT1 down-
regulated tissues. Meanwhile, p-STAT3 (S727) was overexpressed
in both tissues. Statistical analysis of IOD values of tumor tissues is
shown in the histogram (Figure 5A, p,0.05). Conclusively, these
findings indicate that WT1 promotes growth of tumor in vivo and
also depends upon up-regulation of the expression of Cyclin D1
and p-pRb.
6. WT1 Expression Affected the Expression of Cyclin D1
and p-pRb in NSCLC Specimens
We further evaluated the correlation between WT1 expression
and the level of Cyclin D1 and p-pRb with 85 paraffin embedded
human NSCLC tissue slides. Two cases with different WT1
expression levels are shown in Figure 6: Case1 (strong positive) and
Case2 (weak positive). The level of Cyclin D1 and p-pRb was up-
regulated in Case1 compared to Case2. As expected, p-STAT3
(S727) was strongly stained in both Case1 and Case2. This result
supported the hypothesis that WT1 could increase the expression
of Cyclin D1 and p-pRb and regulate the cell cycle.
Discussion
Over the past several decades, although some studies have
investigated the role of WT1 in NSCLC, its function has not been
WT1 Promotes NSCLC Cell Proliferation
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fully elucidated. In this study, we found that the expression of
WT1 gene and protein in NSCLC specimens was markedly up-
regulated compared with adjacent tissues; WT1 promoted
proliferation of NSCLC cells in vitro and vivo, and WT1
expression affected the level of Cyclin D1 and p-pRb which
accelerated cell proliferation in NSCLC cells and clinical
specimens. With all findings taken together, we hypothesized that
WT1 potentially plays an oncogenic role in promoting carcino-
genesis and progression of NSCLC.
WT1 was originally identified as a tumor suppressor gene in
Wilm’s tumor, and was subsequently found to be overexpressed in
a variety of solid tumors [19]. However, the relationship between
expression and carcinogenesis of WT1 in NSCLC remains
controversial. Oji et al. suggested that WT1 might disturb the
growth and differentiation of normal lung cells and contribute to
oncogenesis of lung cancer [11]. More recently, Hayashi S et al
reported that low WT1 gene expression in NSCLC tumors was a
negative prognostic sign and was also associated with lymph node
metastasis [20]. Moreover, it was demonstrated that WT1 loss
induced senescence and decreased proliferation of lung cancer
cells downstream of oncogenic KRAS signalling [21].STAT3 is
constitutively activated in many human tumors such as prostate,
lung, brain, breast and pancreatic cancer [13,15,22,23]. The
downstream genes including Cyclin D1, c-myc, and Bcl-xL of
STAT3, are potentially up-regulated by phosphorylated STAT3.
Cyclin D1 is a cell-cycle regulator that promotes cells from G1-
phase to S-phase, and phosphorylates pRb protein [24], which is a
nuclear phosphoprotein that regulates cell growth in G1-phase.
Hypophosphorylated pRb on S780 then releases E2F from an
inhibitory complex and enables it to promote the transcription
necessary for progression into late G1-phase and S-phase [24–26].
It has been reported that Cyclin D1 and cyclin-depended-kinase 4
(CDK4) phosphorylated pRb and that pRb lost its ability to bind
to E2F [27]. Thus, when Cyclin D1 is up-regulated by STAT3 it
can phosphorylate pRb and promote cell growth by releasing E2F.
Rong et al has reported that the function of WT1 as tumor
suppressor or oncogene was primarily dependent upon the
activities of STAT3. Consequently when STAT3 was activated,
WT1 functioned as a tumor suppressor, but when STAT3 was de-
activated, WT1 functioned as an oncoprotein [18]. They also
proposed that WT1 and STAT3 synergistically promoted cell
proliferation by up-regulating genes such as Cyclin D1 and Bcl-xL.
Based on these results, we hypothesized that WT1 could function
as an oncogene in NSCLC.
In this study, we demonstrated that WT1 was overexpressed in
NSCLC tissues compared with adjacent tissues. WT1 exhibited an
effect on the proliferation of NSCLC cells in vitro and vivo:
overexpression of WT1 promoted cell growth whereas down-
regulation inhibited the proliferation of NSCLC cells. We also
detected expression of STAT3 in NSCLC specimens and cells, in
line with Fernandes et al who found STAT3 overexpressed in lung
cancer tissues [23]. Our results showed that WT1 accelerated S-
phase cell entry; thus, we assessed the cell cycle regulator genes
such as Cyclin D1 and p-pRb and we found that the expression of
Cyclin D1 and p-pRb was indeed up-regulated as shown in
Figure 3D. Taking into consideration our results and the previous
findings of Rong et al, we found that WT1 and STAT3
synergistically promote the growth of NSCLC cells by up-
regulating the cell cycle regulators Cyclin D1 and p-pRb.
Additionally, we found that WT1 expression was associated both
with lymph node metastasis and tumor stage. This result indicates
that WT1 expression may be relevant to tumor invasion and
metastasis. Epithelial to mesenchymal transition (EMT) is consid-
ered an essential process for the metastasis of carcinoma and
dissemination of cancer cells from the primary tumor and
migration to different sites of the body [28]. Interestingly, WT1
could potentially drive EMT via EMT-related targets such as
Snail, Slug and E-cadherin [29–31]. This will require further
research to determine the function of WT1 in tumor invasion and
metastasis.
Unexpectedly, we didn’t find that WT1 had any effect on the
apoptosis of NSCLC cells according to flow cytometer assay and
also by Western-blot assay; this is different from Rong Y et al’s
findings that demonstrated WT1 increased the expression of Bcl-
xL [18]. It was also reported that WT1 is required for inhibition of
apoptosis in breast cancer and rhabdoid cancer by decreasing Bcl-
2 mRNA and protein levels [32,33]; however, other reports
indicated that WT1 negatively regulated the Bcl-2 promoter in the
prostate cell line [34]. Vincent S et al. reported that they did not
detect any difference in response to WT1 depletion in NSCLC cell
lines [21], which was in accordance with our findings. The reason
for these differences remains unknown, but further elucidation, of
why WT1 and STAT3 synergistically promote the level of Cyclin
D1 but have no effect on the level of Bcl-2L in NSCLC, is
warranted. The recently identified transcriptional WT1 co-factors,
such as BASP1 (brain acid-soluble protein 1) and WTIP (WT1
interacting protein) might participate in these differences in WT1-
mediated transcriptional regulation of target genes such as Bcl-2L
[35–37].
In conclusion, in this study, we found a significantly higher
WT1 expression level in NSCLC specimens compared to adjacent
non-cancer tissues, we demonstrated the proliferation promoting
function of WT1 in vitro and in vivo and we identified its
oncogenic role in NSCLC via amplification of the transcriptional
activity of p-STAT3 that up-regulates downstream genes, includ-
ing Cyclin D1 and the hypo-phosphorylated retinoblastoma
protein (p-pRb). Thus, WT1 potentially serve as a therapeutic
target for the treatment of NSCLC.
Supporting Information
Figure S1 The picture of NSCLC wild-type cells and others
transfected with lentivirus in bright light (upper) and in green light
(lower). NSCLC wild-type cells referred as control; cells trans-
duced with pLL3.7 and pLV-GFP referred as GFP1 and GFP2;
cells transduced with pLL3.7-WT1-shRNA referred as WT1-
shRNA and transduced with pLV-GFP-WT1 referred as WT1 in
the figure.
(TIF)
Figure S2 Tumors obtained from the nude mice. Tumors
obtained from the nude mice are all presented in this figure. It
should be noted that we only detected 4 tumors in H1299-WT1-
shRNA group and 5 tumors in H1650-WT1-shRNA group in the
injected site.
(TIF)
Figure S3 WT1 mRNA expression of NSCLC cells. WT1
expression of NSCLC wild-type cells and NSCLC cells transfected
by lentivirus containing pLL3.7 (GFP1), pLV-GFP (GFP2),
pLL3.7-WT1-shRNA (WT1-shRNA1, WT1-shRNA2, WT1-
shRNA3) and pLV-GFP-WT1 (WT1) by Real-time PCR. Data
are represented as mean6SD. *P,0.05.
(TIF)
Table S1 Relationship of WT1 expression and clinicopatholog-
ical features of NSCLC.
(DOC)
Table S2 The sequence of WT1-shRNA.
(DOC)
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